Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1447, 2004-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Is early intervention with biological agents worthwhile in RA?
Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. :
Access to resources
Recommend
Infliximab + methotrexate: the BeST induction therapy for early RA?
Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. :
Infliximab, etanercept worthwhile for RA in Spain?
Inpharma, Vol. 1, Iss. 1449, 2004-01 ,pp. :
Are full or modified HAQ QOL questionnaires best in RA?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 318, 2001-01 ,pp. :
TNF- inhibitors: `new era' of biological therapies for RA?
Inpharma, Vol. 1, Iss. 1267, 2000-01 ,pp. :